Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 6 May 2022 |
| Orion Corporation: Managers' transactions - Maziar Mike Doustdar | 6 May 2022 |
| Orion Corporation: Managers' transactions - Veli-Matti Mattila | 6 May 2022 |
| Orion Corporation: Managers' transactions - Eija Ronkainen | 6 May 2022 |
| Orion Corporation: Managers' transactions - Kari Jussi Aho | 6 May 2022 |
| Orion Corporation: Managers' transactions - Mikael Silvennoinen | 6 May 2022 |